J&J neurology news
Johnson & Johnson said in its 2Q12 earnings that it has reached an agreement in principle with the U.S. Department of Justice to settle three civil False Claims Act matters pending in district court. If the agreements are finalized, they will resolve all federal claims under the federal False Claims Act, all state and federal litigation regarding Omnicare Inc. and heart failure drug Natrecor nesiritide, as well as Medicaid-related claims for antipsychotic Risperdal risperidone.
In 2011, J&J reached an agreement in principle on key issues relevant to a misdemeanor criminal charge related to the promotion of Risperdal, but certain issues remain open before a settlement can be finalized. The government is pursuing criminal and civil actions in the U.S. District Court for the Eastern District of Pennsylvania concerning the sale and marketing of Risperdal and Invega paliperidone and the alleged promotion for off-label uses. In 2009, the government filed suit in the U.S. District Court for the Northern District of California regarding the sales and marketing of Natrecor, a recombinant B-type natriuretic peptide (BNP) vasodilator. The government filed the third suit in 2010 in the U.S. District Court for the District of Massachusetts alleging that the pharma offered kickbacks to Omnicare to increase sales of its drugs, including Risperdal, a long-acting formulation of risperidone. ...